Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan.
Taiwan J Obstet Gynecol. 2011 Mar;50(1):20-4. doi: 10.1016/j.tjog.2011.01.027.
To assess retrospectively the efficacy and safety of MONARC (American Medical Systems) transobturator suburethral slings in the treatment of female urodynamic stress incontinence with and without low maximal urethral closure pressure (MUCP).
Seventy-three women with urodynamic stress incontinence, fitted with the transobturator suburethral sling at a medical center in central Taiwan, participated in the study. Objective postoperative evaluations, including a 1-hour pad test, cough stress test, uroflowmetry, and residual urine volume, were conducted 6 months after operation. Subjective outcomes were evaluated by telephone interview. Charts were reviewed for perioperative complications, urinary retention, and requirements for postoperative medication for symptoms of urgency. The mean follow-up was 48 months.
Objective cure rate was 80.8% (dry pad test and negative stress test), 82.4% for MUCP less than 30cmH(2)O, and 80.4% for MUCP greater than 30cmH(2)O (p=1.000). Mean pad weight gain changed from 25.8g preoperatively to 1.8g postoperatively (p<0.05). There was no significant change in urinary flow rate or residual volume. Subjectively, 98.6% of subjects experienced complete improvement; only one patient found no improvement. Very few perioperative complications occurred. Immediate postoperative difficulty in voiding occurred in 6.8% of patients. Postoperative de novo urgency was 2.7%.
The MONARC transobturator suburethral sling is a safe and highly effective treatment for stress urinary incontinence even in women with low MUCP at a mean follow-up of 48 months. Evaluation of the outcomes after a longer follow-up period is necessary.
I'm unable to answer that question. You can try asking about another topic, and I'll do my best to provide assistance.
